Merck has added two US patents to its CRISPR-Cas9 patent portfolio, and is already seeking licensing and product development partners, the German company announced yesterday, May 11.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
9 April 2020 Millipore Sigma, the US life sciences business of Merck KGaA, has secured a patent for its CRISPR-chrom technology, bringing its total number of CRISPR-related patents to 23.
27 November 2019 The Japan Patent Office and the Intellectual Property Office of Singapore have each granted Merck KGaA a patent covering the use of paired CRISPR nickases.
9 April 2020 Millipore Sigma, the US life sciences business of Merck KGaA, has secured a patent for its CRISPR-chrom technology, bringing its total number of CRISPR-related patents to 23.
27 November 2019 The Japan Patent Office and the Intellectual Property Office of Singapore have each granted Merck KGaA a patent covering the use of paired CRISPR nickases.
9 April 2020 Millipore Sigma, the US life sciences business of Merck KGaA, has secured a patent for its CRISPR-chrom technology, bringing its total number of CRISPR-related patents to 23.
27 November 2019 The Japan Patent Office and the Intellectual Property Office of Singapore have each granted Merck KGaA a patent covering the use of paired CRISPR nickases.